[{"id":"422ad72d-7a97-443d-a2f9-20594b17c5fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01253213","created_at":"2021-01-18T05:03:06.361Z","updated_at":"2024-07-02T16:35:41.488Z","phase":"Phase 1","brief_title":"BR55 in Prostate Cancer: an Exploratory Clinical Trial","source_id_and_acronym":"NCT01253213","lead_sponsor":"Bracco Diagnostics, Inc","biomarkers":" KDR","pipe":" | ","alterations":" KDR expression","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/01/2012","primary_completion_date":" 12/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2023-08-01"},{"id":"863fe75f-2ea4-42b9-b212-5a3e91bd2364","acronym":"","url":"https://clinicaltrials.gov/study/NCT04548271","created_at":"2021-01-18T21:44:42.961Z","updated_at":"2024-07-02T16:36:41.059Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04548271","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • KDR","pipe":" | ","alterations":" PD-L1 expression • KDR expression","tags":["PD-L1 • KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KDR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2020-09-14"},{"id":"eee50566-4809-4235-980c-428fc0234dc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04547088","created_at":"2021-01-18T21:45:03.608Z","updated_at":"2024-07-02T16:36:41.063Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04547088","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • KDR","pipe":" | ","alterations":" PD-L1 expression • KDR expression","tags":["PD-L1 • KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KDR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2020-09-14"},{"id":"1bb4d7b2-4893-4f4d-8e8b-cacb5b89aeb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02072720","created_at":"2021-01-18T09:33:00.104Z","updated_at":"2024-07-02T16:36:54.973Z","phase":"Phase 1","brief_title":"Angiogenic Factor Expression During Fractionated Irradiation","source_id_and_acronym":"NCT02072720","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" KDR • CD31 • PECAM1","pipe":" | ","alterations":" KDR expression • VEGFA expression","tags":["KDR • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2019-10-02"},{"id":"3ede8ad2-acee-4e50-a570-83fc9035aab8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01782313","created_at":"2021-01-18T07:51:26.424Z","updated_at":"2024-07-02T16:36:55.886Z","phase":"Phase 2","brief_title":"A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas","source_id_and_acronym":"NCT01782313","lead_sponsor":"Northwestern University","biomarkers":" KDR • FLT1","pipe":" | ","alterations":" KDR expression • FLT1 expression","tags":["KDR • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression • FLT1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 03/06/2013","start_date":" 03/06/2013","primary_txt":" Primary completion: 05/27/2015","primary_completion_date":" 05/27/2015","study_txt":" Completion: 12/28/2016","study_completion_date":" 12/28/2016","last_update_posted":"2019-09-09"},{"id":"0e4f968b-c3cb-4f7c-8f32-74e6761e836c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01364012","created_at":"2021-01-18T05:35:05.932Z","updated_at":"2024-07-02T16:37:14.237Z","phase":"Phase 3","brief_title":"A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy","source_id_and_acronym":"NCT01364012","lead_sponsor":"Hoffmann-La Roche","biomarkers":" KDR • VEGFA","pipe":" | ","alterations":" KDR expression","tags":["KDR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 276","initiation":"Initiation: 05/23/2011","start_date":" 05/23/2011","primary_txt":" Primary completion: 01/27/2013","primary_completion_date":" 01/27/2013","study_txt":" Completion: 08/17/2017","study_completion_date":" 08/17/2017","last_update_posted":"2018-02-05"},{"id":"f3207bb4-3651-4375-8883-ba5904a6644f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03362086","created_at":"2021-01-18T16:35:43.288Z","updated_at":"2024-07-02T16:37:15.874Z","phase":"","brief_title":"The Osteosarcoma Biobank in Peking University People's Hospital","source_id_and_acronym":"NCT03362086","lead_sponsor":"Peking University People's Hospital","biomarkers":" PD-L1 • KDR","pipe":" | ","alterations":" PD-L1 expression • KDR expression","tags":["PD-L1 • KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KDR expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2017-12-05"}]